ABCA2 as a therapeutic target in cancer and nervous system disorders

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 4, 2008, Pages 491-504

  Mack, Jody T ^a   Brown, Carol B ^a   Tew, Kenneth D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ABCA2; Alzheimer's disease; ATP binding cassette transporters; Cancer stem cell; Drug resistance; Lipid transport; Myelin

Indexed keywords

2,2' AZOBIS(2 AMIDINOPROPANE); ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER A2; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; GEMCITABINE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; METHOTREXATE; MINICHROMOSOME MAINTENANCE PROTEIN 7; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VINBLASTINE; ABCA2 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BREAST CANCER; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COLORECTAL CANCER; DEMYELINATING DISEASE; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC LINKAGE; GLIOMA; HUMAN; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MEDLINE; MYELINATION; NEOPLASM; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; ONSET AGE; PATHOGENESIS; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUBLICATION; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CANCER STEM CELL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYELIN SHEATH; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; MYELIN SHEATH; NEOPLASMS; NEOPLASTIC STEM CELLS; NERVOUS SYSTEM DISEASES;

EID: 42149113063     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.4.491     Document Type: Review

References (105)

1. Higgins CF. ABC transporters: from microorganisms to man. Ann Rev Cell Biol 1992;8:67-113
2. Linton KJ. Structure and function of ABC transporters. Physiology (Bethesda) 2007;22:122-30
3. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461(2):237-62
4. Iida A, Saito S, Sekine A, et al. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 2002;47(6):285-310
5. Holland IB, Blight MA. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol 1999;293(2):381-99
6. Hollenstein K, Dawson RJ, Locher KP. Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol 2007;17:1-7
7. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11(10):918-26
8. Albrecht C, Viturro E. The ABCA subfamily - gene and protein structures, functions and associated hereditary diseases. Pflugers Arch 2007;453(5):581-9
9. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 1999;39:361-98
10. Luciani MF, Denizot F, Savary S, et al. Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 1994;21(1):150-9
11. Kikuno R, Nagase T, Ishikawa K, et al. Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 1999;6(3):197-205
12. Zhao LX, Zhou CJ, Tanaka A, et al. Cloning, characterization and tissue distribution of the rat ATP-binding cassette (ABC) transporter ABC2/ ABCA2. Biochem J 2000;350(Pt 3):865-72
13. Kaminski WE, Piehler A, Pullmann K, et al. Complete coding sequence, promoter region, and genomic structure of the human ABCA2 gene and evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 2001;281(1):249-58
14. Vulevic B, Chen Z, Boyd JT, et al. Cloning and characterization of human adenosine 5′-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res 2001;61(8):3339-47
15. Tanaka Y, Yamada K, Zhou CJ, et al. Temporal and spatial profiles of ABCA2-expressing oligodendrocytes in the developing rat brain. J Comp Neurol 2003;455(3):353-67
16. Zhou CJ, Inagaki N, Pleasure SJ, et al. ATP-binding cassette transporter ABCA2 (ABC2) expression in the developing spinal cord and PNS during myelination. J Comp Neurol 2002;451(4):334-45
17. Saito T, Yamada K, Wang Y, et al. Expression of ABCA2 protein in both non-myelin-forming and myelin-forming Schwann cells in the rodent peripheral nerve. Neurosci Lett 2007;414(1):35-40
18. Wang Y, Yamada K, Tanaka Y, et al. Expression of ABCA2 protein in human vestibular schwannoma and peripheral nerve. J Neurol Sci 2005;232(1-2):59-63
19. Mack JT, Townsend DM, Beljanski V, Tew KD. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr Drug Metab 2007;8(1):47-57
20. Davis W Jr, Chen ZJ, Ile KE, Tew KD. Reciprocal regulation of expression of the human adenosine 5′-triphosphate binding cassette, sub-family A, transporter 2 (ABCA2) promoter by the early growth response-1 (EGR-1) and Sp-family transcription factors. Nucleic Acids Res 2003;31(3):1097-107
21. Ile KE, Davis W Jr, Boyd JT, et al. Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim Biophys Acta 2004;1678(1):22-32
22. Schmitz G, Kaminski WE. ABCA2: a candidate regulator of neural transmembrane lipid transport. Cell Mol Life Sci 2002;59(8):1285-95
23. Fitzgerald ML, Okuhira KI, Short GF 3rd, et al. ABCA1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and apoA-I binding activities. J Biol Chem 2004;279(46):48477-85
24. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92(16):1295-302
25. Davis W Jr, Boyd JT, Ile KE, Tew KD. Human ATP-binding cassette transporter-2 (ABCA2) positively regulates low-density lipoprotein receptor expression and negatively regulates cholesterol esterification in Chinese hamster ovary cells. Biochim Biophys Acta 2004;1683(1-3):89-100
26. Sakai H, Tanaka Y, Tanaka M, et al. ABCA2 deficiency results in abnormal sphingolipid metabolism in mouse brain. J Biol Chem 2007;282(27):19692-9
27. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232(4746):34-47
28. Smith JR, Osborne TF, Goldstein JL, Brown MS. Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J Biol Chem 1990;265(4):2306-10
29. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999;22(4):347-51
30. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22(4):336-45
31. McNeish J, Aiello RJ, Guyot D, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 2000;97(8):4245-50
32. Singaraja RR, Bocher V, James ER, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem 2001;276(36):33969-79
33. Mack JT, Beljanski V, Soulika AM, et al. "Skittish" Abca2 knockout mice display tremor, hyperactivity, and abnormal myelin ultrastructure in the central nervous system. Mol Cell Biol 2007; 27(1):44-53
34. Kim WS, Rahmanto AS, Kamili A, et al. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-β peptide generation. J Biol Chem 2007;282(5):2851-61
35. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91(1):54-69
36. Molony T. Use of cholesterol drugs may decrease breast cancer risk. J Dent Hyg 2003;77(4):214
37. Michaud DS, Giovannucci E, Willett WC, et al. Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 2003;157(12):1115-25
38. Siemianowicz K, Gminski J, Stajszczyk M, et al. Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med 2000;6(3):307-11
39. Tatidis L, Gruber A, Vitols S. Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. J Lipid Res 1997;38(12):2436-45
40. Lum DF, McQuaid KR, Gilbertson VL, Hughes-Fulford M. Coordinate up-regulation of low-density lipoprotein receptor and cyclo-oxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies. Int J Cancer 1999;83(2):162-6
41. Kim J, Adam RM, Solomon KR, Freeman MR. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 2004;145(2):613-9
42. Gylling H, Pyrhonen S, Mantyla E, et al. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 1995;13(12):2900-5
43. Mastroianni A, Bellati C, Facchetti G, et al. Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapy. Clin Biochem 2000;33(6):513-6
44. Brower V. Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 2003;95(12):844-6
45. Laing NM, Belinsky MG, Kruh GD, et al. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res 1998;58(7):1332-7
46. Efferth T, Gillet JP, Sauerbrey A, et al. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2006;5(8):1986-94
47. Boonstra R, Timmer-Bosscha H, Van Echten-Arends J, et al. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer 2004;90(12):2411-7
48. Chen ZJ, Vulevic B, Ile KE, et al. Association of ABCA2 expression with determinants of Alzheimer's disease. FASEB J 2004;18(10):1129-31
49. Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res 2005;65(8):2993-5
50. Weiss SW GJ. Benign tumors of peripheral nerves. In: Enzinger and Weiss's Soft Tissue Tumors. Weiss SW GJ editor. Mosby, Inc., St. Louis; 2001. p. 1111-207
51. Soichi O, Masanori N, Hideo T, et al. Clinical significance of ABCA2′ a possible molecular marker for oligodendrogliomas. Neurosurgery 2007;60(4):707-14; discussion 714
52. Steinbach D, Gillet JP, Sauerbrey A, et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006;12(14 Pt 1):4357-63
53. De Jonge-Peeters SD, Kuipers F, De Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007;62(3):214-26
54. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42(7):1007-17
55. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2(1):48-58
56. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5(3):219-34
57. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22(47):7468-85
58. Punzi JS, Duax WL, Strong P, et al. Molecular conformation of estramustine and two analogues. Mol Pharmacol 1992;41(3):569-76
59. Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005;65(6 Suppl):8-12
60. Gillet JP, Efferth T, Steinbach D, et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 2004;64(24):8987-93
61. Tiersten AD, Nelsen C, Talbot S, et al. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer 2003;97(3):537-44
62. Rosenthal MA, Gruber ML, Glass J, et al. Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2000;47(1):59-63
63. Borghaei H, Millenson M, Schilder R, et al. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer 2004;101(9):2034-41
64. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26(9):1357-60
65. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5(4):275-84
66. Wulf GG, Wang RY, Kuehnle I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98(4):1166-73
67. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983-8
68. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432(7015):396-401
69. Haraguchi N, Utsunomiya T, Inoue H, et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006;24(3):506-13
70. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006;44(1):240-51
71. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007;67(10):4827-33
72. Rinehart JJ, Wuest D, Ackerman GA. Corticosteroid alteration of human monocyte to macrophage differentiation. J Immunol 1982;129(4):1436-40
73. Broccardo C, Nieoullon V, Amin R, et al. ABCA2 is a marker of neural progenitors and neuronal subsets in the adult rodent brain. J Neurochem 2006;97(2):345-55
74. De Grouw EP, Raaijmakers MH, Boezeman JB, et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia 2006;20(4):750-4
75. Chen G, Zhuchenko O, Kuspa A. Immune-like phagocyte activity in the social amoeba. Science 2007;317(5838):678-81
76. Wang Z, Wang J, Tantoso E, et al. Signatures of recent positive selection at the ATP-binding cassette drug transporter superfamily gene loci. Hum Mol Genet 2007;16(11):1367-80
77. Mace S, Cousin E, Ricard S, et al. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiol Dis 2005;18(1):119-25
78. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003;6(4):345-51
79. Tian J, Shi J, Mann DM. Cerebral amyloid angiopathy and dementia. Panminerva Med 2004;46(4):253-64
80. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001;32(2):181-4
81. Laferla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer's disease. Nat Rev Neurosci 2007;8(7):499-509
82. Thinakaran G. The role of presenilins in Alzheimer's disease. J Clin Invest 1999;104(10):1321-7
83. Papassotiropoulos A, Streffer JR, Tsolaki M, et al. Increased brain β-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003;60(1):29-35
84. Katzov H, Chalmers K, Palmgren J, et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to β-amyloid metabolism. Hum Mutat 2004;23(4):358-67
85. Wollmer MA, Kapaki E, Hersberger M, et al. Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2006;141(5):534-6
86. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004;363(9415):1139-46
87. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322(7300):1447-51
88. Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol 2004;15(6):667-72
89. Refolo LM, Pappolla MA, Lafrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001;8(5):890-9
90. Yanagisawa K. Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta 2007;1768(8):1943-51
91. Jin L-W, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-β precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 2004;164:975-85
92. Noble M. The possible role of myelin destruction as a precipitating event in Alzheimer's disease. Neurobiol Aging 2004;25(1):25-31
93. Zhou C, Zhao L, Inagaki N, et al. ATP-binding cassette transporter ABC2/ ABCA2 in the rat brain: a novel mammalian lysosome-assaciated membrane protein and a specific marker for oligodendrocytes but not for myelin sheaths. J Neurosci 2001;21(3):849-57
94. Oliver PL, Davies KE. Analysis of human neurological disorders using mutagenesis in the mouse. Clin Sci (Lond) 2005;108(5):385-97
95. Oram JF. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr Opin Lipidol 2002;13(4):373-81
96. Yamano G, Funahashi H, Kawanami O, et al. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 2001;508(2):221-5
97. Ban N, Matsumura Y, Sakai H, et al. ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem 2007;282(13):9628-34
98. Cheong N, Zhang H, Madesh M, et al. ABCA3 is critical for lamellar body biogenesis in vivo. J Biol Chem 2007;282(33):23811-7
99. Fitzgerald ML, Xavier R, Haley KJ, et al. ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol. J Lipid Res 2007;48(3):621-32
100. Radu RA, Mata NL, Bagla A, Travis GH. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt's macular degeneration. Proc Natl Acad Sci USA 2004;101(16):5928-33
101. Weng J, Mata NL, Azarian SM, et al. Insights into the function of Rim protein us photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 1999;98(1):13-23
102. Kubo Y, Sekiya S, Ohigashi M, et al. ABCA5 resides in lysosomes, and ABCA5 knockout mice develop lysosomal disease-like symptoms. Mol Cell Biol 2005;25(10):4138-49
103. Kaminski WE, Piehler A, Wenzel JJ. ABC A-subfamily transporters: structure, function and disease. Biochim Biophys Acta 2006;1762(5):510-24
104. Wang N, Lan D, Gerbod-Giannone M, et al. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J Biol Chem 2003;278(44):42906-12
105. Kim WS, Fitzgerald ML, Kang K, et al. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J Biol Chem 2005;280(5):3989-95